Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Historic psychedelic drug trials and the treatment of anxiety disorders.
Weston NM, Gibbs D, Bird CIV, Daniel A, Jelen LA, Knight G, Goldsmith D, Young AH, Rucker JJ. Weston NM, et al. Among authors: bird civ. Depress Anxiety. 2020 Dec;37(12):1261-1279. doi: 10.1002/da.23065. Epub 2020 Jul 5. Depress Anxiety. 2020. PMID: 32627308
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.
Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, Lennard-Jones M, Mistry S, Saldarini F, Stansfield S, Tai SJ, Williams S, Weston N, Malievskaia E, Young AH. Rucker JJ, et al. J Psychopharmacol. 2022 Jan;36(1):114-125. doi: 10.1177/02698811211064720. Epub 2022 Jan 4. J Psychopharmacol. 2022. PMID: 35090363 Free PMC article. Clinical Trial.
Springtime for psychopharmacology.
Bird C, Young AH. Bird C, et al. J Psychopharmacol. 2022 Mar;36(3):249-251. doi: 10.1177/02698811221085764. J Psychopharmacol. 2022. PMID: 35253515 No abstract available.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Goodwin GM, et al. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. N Engl J Med. 2022. PMID: 36322843 Clinical Trial.
The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls.
Lawn W, Mokrysz C, Lees R, Trinci K, Petrilli K, Skumlien M, Borissova A, Ofori S, Bird C, Jones G, Bloomfield MA, Das RK, Wall MB, Freeman TP, Curran HV. Lawn W, et al. J Psychopharmacol. 2022 Dec;36(12):1350-1361. doi: 10.1177/02698811221108956. Epub 2022 Jun 30. J Psychopharmacol. 2022. PMID: 35772419 Free PMC article.